Fangda represented Quan Capital as co-lead investors in its equity investment in the Series B financing of Oricell, involving a transaction price of over USD120 million

The press releases published in this section have been uploaded by law firms. Their content has not been appraised or edited by Law.asia, and no responsibility is taken for the accuracy of the information they contain or any misrepresentation therein. For our independent editorial content, please visit our homepage.

Fangda represented Quan Capital as co-lead investors in its equity investment in the Series B financing of Oricell, involving a transaction price of over USD120 million

Description

  • Fangda Partners represented Quan Capital as co-lead investors in its equity investment in the Series B financing of Oricell, involving a transaction price of over USD120 million. The transaction was publicized on August 1, 2022. The Fangda team on this deal was led by Helen Fan and Samuel Xie. Fangda handled legal due diligence, documents review, revise and negotiation. Oricell is a leading enterprise dedicated to develop tumor immunotherapy.

  • image-9605
2022-09-16
REGION:
  • China

Tell others about this press release

[addthis tool="addthis_inline_share_toolbox_9u03"]